Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study

Autor:	Rikiya Nakamura, Masahiro Kashiwaba, Diana B. Cherbavaz, Hironobu Sasano, Kentaro Sakamaki, Debbie M Jakubowski, Hiromitsu Akabane, Naoko Sugiyama, Yoshie Hasegawa, Naruto Taira, Takehiko Sakai, Norikazu Masuda, Takuhiro Yamaguchi, Tomomi Fujisawa, Helen Bailey, Shoichiro Ohtani, Calvin Chao, Yukiko Shibahara, Yasuo Ohashi, Tatsuya Toyama, Hiroji Iwata, Yutaka Yamamoto
Rok vydání:	2018
Předmět:	0301 basic medicine Oncology Cancer Research medicine.medical_specialty Receptor ErbB-2 Breast surgery medicine.medical_treatment Phases of clinical research Antineoplastic Agents Breast Neoplasms Mastectomy Segmental 03 medical and health sciences Oncotype DX 0302 clinical medicine Breast cancer Internal medicine medicine Clinical endpoint Biomarkers Tumor Humans Neoadjuvant therapy Mastectomy Aged medicine.diagnostic_test business.industry Letrozole Gene Expression Profiling Recurrence score Middle Aged medicine.disease Clinical Trial Neoadjuvant Therapy Gene Expression Regulation Neoplastic 030104 developmental biology Treatment Outcome Receptors Estrogen 030220 oncology & carcinogenesis Hormonal therapy Female Neoplasm Recurrence Local Neoadjuvant business medicine.drug
Zdroj:	Breast Cancer Research and Treatment
ISSN:	1573-7217
Popis:	Purpose The Recurrence Score test is validated to predict benefit of adjuvant chemotherapy. TransNEOS, a translational study of New Primary Endocrine-therapy Origination Study (NEOS), evaluated whether Recurrence Score results can predict clinical response to neoadjuvant letrozole. Methods NEOS is a phase 3 clinical trial of hormonal therapy ± adjuvant chemotherapy for postmenopausal patients with ER+, HER2-negative, clinically node-negative breast cancer, after six months of neoadjuvant letrozole and breast surgery. TransNEOS patients had tumors ≥ 2 cm and archived core-biopsy samples taken before neoadjuvant letrozole and subsequently sent for Recurrence Score testing. The primary endpoint was to evaluate clinical (complete or partial) response to neoadjuvant letrozole for RS
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87e8b31e705bc60fce81d00a8d29d94e https://pubmed.ncbi.nlm.nih.gov/30242578 Zobrazit plný text záznamu Full text from SpringerLink